Anticardiolipin antibodies and risk of thromboembolic disease in young Jamaican women

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 6, 2001, Pages 349-354

  Kahwa, Eulalia K ^a   Mcfarlane Anderson, Norma ^b   Smikle, Monica F ^c   Forrester, Terrence ^a   Wilks, Rainford J ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b Department of Biochemistry ^*  (Jamaica)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

anticardiolipin antibodies; antiphospholipid antibodies; Jamaica; myocardial infarction; stroke; venous thromboembolism; women

Indexed keywords

ALCOHOL; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; ORAL CONTRACEPTIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY DETECTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; JAMAICA; ORAL CONTRACEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; VARICOSIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CHI-SQUARE DISTRIBUTION; FEMALE; GLYCOPROTEINS; HUMANS; HYPERTENSION; JAMAICA; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTORS; THROMBOEMBOLISM;

EID: 0035698039     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800603     Document Type: Article

References (35)

1. Harris E, Gharavi AE, Hughes GV. Antiphospholipid antibodies. Clin Rheum Dis 1985; 11: 591–609.
2. Harris EN. Annotation. Br J Haematol 1990; 74: 1–9.
3. McNeil HP, Simpson RJ, Chesterman CN, Krillis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: Beta 2 glycoprotein 1 (Apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4124.
4. Galli M, Comfurious P, Maasen C, Henkel HC, de Baets MH, van Breda-Vriesman PJC, et al Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547.
5. Matsuura H, Igarasha Fujimoto M, Ichikawa K, Koike T. Anticardiolipin co-factors and diagnosis of autoimmune disease. Lancet 1990; 336: 1771–1787.
6. Lockshin MD. Antiphospholipid antibody and antiphospholipid antibody syndrome. Curr Opin Rheumatol 1991; 3: 797–802.
7. Asherson RA, Khamashta MA, Ordi- Ros J, Derksen RH, Marchin S, Barquinero J, et al The primary antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989; 68: 366–374.
8. Samaritano LR, Gharavi AE, Lokshin MD. Antiphospholipid antibody syndrome: Immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20: 81–96.
9. Bick RL. Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and management. Int J Haematol 1997; 65: 193–213.
10. Zielynska J, Ryglewickz D, Wierzchowska E, Lechowicz W, Heir DB, Czlonkowska A. Anticardiolipin antibodies are an independent risk factor for ischaemic stroke. Neurol Res 1999; 21: 653–657.
11. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for ischaemic stroke. Neurology 1993; 43: 2069–2073.
12. Ginzburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al Anticardiolipin antibodies and the risk for ischaemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997–1002.
13. Ahmed E, Stegmayr B, Trifnovick J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke. An incident case—referent study nested within the MONICA and Vasterbotten cohort project. Stroke 2000; 31: 1289–1293.
14. Vaarala O, Manttari M, Manninen V, Tenkannen L, Puurunen M, Aho K, et al Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23–27.
15. Forrester TF, Wilks R, Bennet F, McFarlane-Anderson N, McGhee D, Cooper R, et al Obesity in the Caribbean. In: Chadwick DJ, Cardew G, editors. The Origins and Consequences of Obesity Ciba Foundation Symposium 201. Chichester: John Wiley #38;#38; Sons, 1996. pp. 17–31.
16. Statistical Institute of Jamaica. Demographic statistics 1999; STATIN, Kingston 2000.
17. Zeller K, Siostrzoneck P, Lang W, Gossinger H, Oder W, Ciciyasvilli H, et al Different risk factor profiles in young and elderly stroke patients with special reference in cardiac disorders. J Clin Epidemiol 1992; 45: 1383–1389.
18. Carolei A, Marini C, Ferranti E, Frontoni M, Massimiliano P, Fieschi C. A prospective study of cerebral ischaemia in the young. Analysis of pathogenic determinants. Stroke 1993; 24: 362–367.
19. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic Stroke and combined oral contraceptives: Results of international, multicentre, case—control study. Lancet 1996; 348: 498–510.
20. Tunstall-Pedoe H. WHO Monica Project (Monitoring of trends and determinants in cardiovascular disease): A major international collaboration. J Clin Epidemiol 1988; 41: 105–114.
21. Harris EN. The Second International Anti-Cardiolipin Standardization Workshop: The Kingston Anti-phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 476–484.
22. Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia: Predictive value of the anticardiolipin test. Arch Intern Med 1986; 146: 2153–2156.
23. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193–280.
24. Silver RM, Porter TF, Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: Clinical consequences of ‘low titres’. Obstet Gynecol 1996; 87: 494–500.
25. McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of anti-β2 glycoprotein 1 assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471–473.
26. Haviv YS. Association of anticardiolipin antibodies with vascular injury: Possible mechanisms. Postgrad Med J 2000; 76: 625–628.
27. Schousboe I. β2 glycoprotein1: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1995; 66: 1086–1091.
28. Nimpf J, Wurm H, Kostner GM. β2 glycoprotein1 (apoH) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109–114.
29. Nimpf J, Bevers EM, Bomars PHH, Till U, Wurm H, Kostner GM, et al Prothrombinase activity of human platelets is inhibited by β2 glycoprotein1. Biochim Biophys Acta 1986; 884: 142–149.
30. Roubey RAS, Harper MF, Lentz BR. The interaction of β2 glycoprotein1 with phospholipid membranes. Arthritis Rheum 1995; 38 (suppl 9): S352.
31. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101–107.
32. Oosting JD, Derksen RH, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanisms? Blood 1993; 81: 2618–2626.
33. Khamashta MA, Harris EN, Gharavi AE, Hughes GRV. Immune mediated mechanisms for thrombosis: Antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 849–853.
34. Pierangelli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 1361–1367.
35. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569–573.